First up is the ADEPT study in bullous pemphigoid (BP), a rare skin condition that leads to reddening of the skin and the formation of painful and intensely itchy chronic lesions and blisters ...

EYLEA HD is anticipated to gain traction with the launch of a prefilled syringe in mid-2025 and label expansions for macular edema and extended dosing intervals. Management believes these developments ...

A 58-year-old male patient presented to the dermatology clinic at West China Hospital of Sichuan University (Chengdu, Sichuan ...

Blue Trust Inc. increased its stake in argenx SE (NASDAQ:ARGX – Free Report) by 46.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor ...

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in the ...

and the French drugmaker is also eyeing testing it in phase 2 and 3 trials in chronic obstructive pulmonary disease (COPD), bullous pemphigoid, prurigo nodularis, chronic hives, and allergies.

This entity was first described by Chorzelski and Jablonska from Warsaw Center of Bullous Diseases ... We as a first published a case of anti-p200kD pemphigoid mediated by IgA. Our immunoelectron ...